Cargando…
Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
Recently, the use of immunotherapy has increased substantially for the treatment of several malignancies. It is associated with several gastrointestinal adverse events; however, severe complications such as intestinal perforation are rare. We present a 75-year-old man with metastatic melanoma, prese...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762925/ https://www.ncbi.nlm.nih.gov/pubmed/36561494 http://dx.doi.org/10.14309/crj.0000000000000900 |
_version_ | 1784852953123782656 |
---|---|
author | Bakhshwin, Ahmed Robertson, Jessica Sarwate, Mrinal Roberts, Daniel |
author_facet | Bakhshwin, Ahmed Robertson, Jessica Sarwate, Mrinal Roberts, Daniel |
author_sort | Bakhshwin, Ahmed |
collection | PubMed |
description | Recently, the use of immunotherapy has increased substantially for the treatment of several malignancies. It is associated with several gastrointestinal adverse events; however, severe complications such as intestinal perforation are rare. We present a 75-year-old man with metastatic melanoma, presented with profuse diarrhea and abdominal pain, after ipilimumab and nivolumab administration. Shortly after, he developed fulminant colitis and intestinal perforation and was found to have concurrent Rosai-Dorfman disease of pericolonic lymph nodes. With the increasing use of immunotherapy, reporting of serious adverse events and their mimics is essential. In addition, further studies are required to investigate whether an association exists between Rosai-Dorfman disease and immunotherapy. |
format | Online Article Text |
id | pubmed-9762925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-97629252022-12-21 Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease Bakhshwin, Ahmed Robertson, Jessica Sarwate, Mrinal Roberts, Daniel ACG Case Rep J Case Report Recently, the use of immunotherapy has increased substantially for the treatment of several malignancies. It is associated with several gastrointestinal adverse events; however, severe complications such as intestinal perforation are rare. We present a 75-year-old man with metastatic melanoma, presented with profuse diarrhea and abdominal pain, after ipilimumab and nivolumab administration. Shortly after, he developed fulminant colitis and intestinal perforation and was found to have concurrent Rosai-Dorfman disease of pericolonic lymph nodes. With the increasing use of immunotherapy, reporting of serious adverse events and their mimics is essential. In addition, further studies are required to investigate whether an association exists between Rosai-Dorfman disease and immunotherapy. Wolters Kluwer 2022-12-19 /pmc/articles/PMC9762925/ /pubmed/36561494 http://dx.doi.org/10.14309/crj.0000000000000900 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Report Bakhshwin, Ahmed Robertson, Jessica Sarwate, Mrinal Roberts, Daniel Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease |
title | Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease |
title_full | Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease |
title_fullStr | Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease |
title_full_unstemmed | Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease |
title_short | Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease |
title_sort | perforating colitis secondary to immune checkpoint inhibitor use in a patient with pericolonic involvement by rosai-dorfman disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762925/ https://www.ncbi.nlm.nih.gov/pubmed/36561494 http://dx.doi.org/10.14309/crj.0000000000000900 |
work_keys_str_mv | AT bakhshwinahmed perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease AT robertsonjessica perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease AT sarwatemrinal perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease AT robertsdaniel perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease |